Cell/Gene Tx channel feed – Endpoints News

Cell/Gene Tx channel feed

Scoop: Gilead’s CAR-T player Kite waves goodbye to research chief Peter Emtage as another top exec hits the exit

5 years ago

MiNA Therapeutics bags nearly $30M Series A to push activating mRNA tech through the clinic

5 years ago

Closely-watched international CRISPR ethics panel leaves door ajar for germline editing — one day

5 years ago

Researchers at City of Hope combine oncolytic virus with a CAR-T to eradicate solid tumors in mice

5 years ago

Researchers teamed up to develop a 'three in one' HIV treatment — and the NIH is throwing in $14.6M

5 years ago

Crossover round? Check. Top team? Check. Taysha sails to an IPO with $100M initial ask

5 years ago

Game change: A frontrunner in the cell therapy 2.0 field offers a first look at their lead therapy. And it’s a doozy

5 years ago

Sold for pennies, Unum gets one last shot at redemption

5 years ago

Synthego adds $100M from RA, Wellington, 8VC in pursuit of 'virtualizing biology'

5 years ago

Derailed gene therapy study reports 3rd death as safety and durability issues cloud a booming field

5 years ago

Daniel O’Day’s I/O dance continues, as Gilead and Tango expand deal up to $6B

5 years ago

Taysha buys clinic-ready gene therapy from Abeona, bringing Steven Gray's portfolio back in one place

5 years ago

Teamed up with Lyell, Juno/WuXi joint venture files IPO betting on China's CAR-T future

5 years ago

BioMarin CSO disses rivals for the hemophilia A gene therapy crown: Way behind, facing big recruitment challenges and at best a .6 on the gen-one scale

5 years ago

Novartis’ CAR-T partner in China wraps $383M take-private deal engineered by CEO

5 years ago

CF Foundation, Longwood team on new incubator for companies with cutting-edge CF treatments

5 years ago

FDA hands MorphoSys and Incyte a quick OK on their potential blockbuster CAR-T alternative

5 years ago

Codiak gets a competitor, as Mantra Bio leaves stealth and enters growing exosome space

5 years ago

'Exquisite control': Flagship pulls off $85M rally around Omega Therapeutics' clinical push for epigenetic programming tech

5 years ago

Can progenitor cells go further than gene therapy in retinal disorders? A biotech's answer shines in PhIIb

5 years ago

Gilead’s Kite snares a landmark FDA OK on a $373,000 CAR-T therapy — which comes with bragging rights to the first true franchise op

5 years ago

'Missing link': Bayer, Morningside help catapult a new kind of delivery tech to cell and gene therapy

5 years ago

GV's David Schenkein comes in to help mentor — and bankroll — a gene therapy 2.0 player, intrigued by their ‘science heavy’ approach to conquering severe disease

5 years ago

Juno/WuXi's cell therapy venture buys out solid tumor player in China, gaining a discovery engine and portending more M&A to come

5 years ago

First page Previous page 44 45 464748 49 50 Next page Last page